| 邵晶 刘敬杨 徐睿玲 胡颖 刘冰熔△.注射液胸腺法新（日达仙）辅助希罗达联合奥沙利铂（XELOX方案）治疗
晚期胃癌的临床疗效观察[J].,2016,16(23):4469-4471 |
| 注射液胸腺法新（日达仙）辅助希罗达联合奥沙利铂（XELOX方案）治疗
晚期胃癌的临床疗效观察 |
| Observation on the Clinical Efficacy of Thymosin Alpha-1 for Injection(Zadaxin) Plus Capecitabine Tablets Combined with Oxaliplatin in theTreatment of Advanced Gastric Cancer |
| |
| DOI： |
| 中文关键词: 日达仙 晚期胃癌 生活质量 治疗效果 免疫功能 |
| 英文关键词: Zadaxin Advanced gastric cancer Quality of life Treatment effect Immune function |
| 基金项目:国家自然科学基金项目(30871152) |
|
| 摘要点击次数: 883 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的：探讨注射液胸腺法新（日达仙）辅助希罗达联合奥沙利铂治疗晚期胃癌的临床疗效和对患者免疫功能及生活质量的
影响。方法：选择2010-2013 入院治疗的晚期胃癌患者116 例，随机平均分为实验组（58例）和对照组（58 例）。对照组给予卡培他
滨片（希罗达）联合奥沙利铂，试验组在对照组的基础上辅用注射液胸腺法新（日达仙）治疗。每治疗两到三个周期后进行一次系
统疗效评估，评估项目包括影像学腹部CT、胸片、腹部彩超、血常规、尿常规、肝功、肾功，肿瘤标记物癌胚抗原（CEA）、糖类抗原
（CA19-9,CA72-4)、免疫指标CD3+、CD8+、CD4/CD8、NK细胞，总治疗周期为6-8个周期。结果：实验组疾病治疗有效率为48%，对
照组有效率为29%，两组比较差异具有统计学意义（p=0.041），实验组患者中位无疾病进展期（PFS）为12.5 月，显著高于对照组
10.1 月，两组比较具有统计学意义（P<0.05）。实验组患者生活质量评分、外周血CD3+、CD8+、CD4/CD8 、NK 细胞数量均显著优于
对照组（P<0.05）。结论：注射液胸腺法新（日达仙）辅助希罗达联合奥沙利铂（XELOX 方案）能够提高晚期胃癌的临床疗效，改善
患者的生活质量和免疫力，减少患者化疗用药的毒副反应。 |
| 英文摘要: |
| Objective:To study the therapeutical efficacy of Thymosin Alpha-1 for Injection (Zadaxin) plus Capecitabine Tablets
combined with oxaliplatin in treatment of advanced gastric cancer and its efficts on immune function an quality of living.Methods:116
patients with advanced gastric cancer were randomly divided into control group(n=58) and observation group (n=58). the patients in control
group were give Capecitabine Tablets(850~1000 mg/m2 Bid po d1-14) combined with oxaliplatin(130mg/m2 ivgtt d1). And observation
group give Zadaxin(1.6mg Biw) plus Capecitabine Tablets combined with oxaliplatin. Three weeks were difined as one circle and total
circles were 6-8 circles. The therapeutical efficiency and quality of living were evalued according to WHO efficiency and ECOG,
Karnofdky score.The immune function were according to the changes of CD3+, CD8+, CD4/CD8 and NK cells before and after the treatment.Results:The significant statistical differences in treatment efficiency and disease control rate between the control and observation
group (P<0.05). The median without progressed for the observation group (12.5 months) significantly higher than the control group(10.1
months). After three circles treatment the CD3+, CD8+, CD4/CD8 and NK cells in the observation group were significantly higher than of the control group (P<0.05 ).Conclusion:Zadaxin plus Capecitabine Tablets combined with oxaliplatin could extend the median progression
free survival time and immune function in the treatment of advanced gastric cancer patients. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
